Literature DB >> 31870843

Agonism of GPR120 prevents ox-LDL-induced attachment of monocytes to endothelial cells.

Tiechao Jiang1, Dongli Jiang2, Dong You3, Lirong Zhang4, Long Liu5, Qini Zhao6.   

Abstract

Oxidized low-density lipoprotein (ox-LDL)-induced endothelial inflammation plays an important role in the development of cardiovascular diseases. G protein-coupled receptors (GPCR) are gaining traction as potential treatment targets due to their roles in mediating a wide range of physiological processes. GPR120 is a recently identified omega-3 fatty acid receptor. We hypothesized that agonism of GPR120 might attenuate ox-LDL-induced endothelial dysfunction. In the present study, we tested the effects of two GPR120 agonists-GW9508 and TUG-891-in mitigating endothelial insult induced by ox-LDL in human aortic endothelial cells (HAECs). Real-time PCR, western blot, and ELISA analyses were used in our experiments. Our findings demonstrate that GPR120 is downregulated by exposure to ox-LDL, suggesting a role for GPR120 in mediating ox-LDL insult. Furthermore, we found that agonism of GPR120 could suppress oxidative stress and inflammation by inhibiting the production of reactive oxygen species and the expression of proinflammatory cytokines. Importantly, we show that agonism of GPR120 prevents the attachment of monocytes to endothelial cells by suppressing the expression of VCAM-1 and E-selectin. Finally, we show that agonism of GPR120 exerts a remarkable atheroprotective effect by elevating the expression level of Krüppel-like factor 2 (KLF2). Together, our results demonstrate a potential role for specific agonism of GPR120 in the prevention of endothelial damages induced by ox-LDL.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; E-selectin; GPR120; HAECs; KLF2; Monocyte adhesion; Oxidative stress; VCAM-1; ox-LDL

Mesh:

Substances:

Year:  2019        PMID: 31870843     DOI: 10.1016/j.cbi.2019.108916

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

1.  CircRNA-PTPRA Knockdown Inhibits Atherosclerosis Progression by Repressing ox-LDL-Induced Endothelial Cell Injury via Sponging of miR-671-5p.

Authors:  Xueting Luo; Xiaoli Zhou
Journal:  Biochem Genet       Date:  2022-07-11       Impact factor: 2.220

2.  5,2'-Dibromo-2,4',5'-trihydroxydiphenylmethanone Inhibits LPS-Induced Vascular Inflammation by Targeting the Cav1 Protein.

Authors:  Hongxia Yuan; Qianyi Hou; Xiue Feng; Yuanlin Zhang; Fan Yang; Rui Ge; Qingshan Li
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

Review 3.  Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4).

Authors:  Anna Kiepura; Kamila Stachyra; Rafał Olszanecki
Journal:  Biomedicines       Date:  2021-04-24

Review 4.  The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy.

Authors:  Siarhei A Dabravolski; Vasily N Sukhorukov; Vladislav A Kalmykov; Andrey V Grechko; Nikolay K Shakhpazyan; Alexander N Orekhov
Journal:  Biomedicines       Date:  2022-01-24

Review 5.  FFAR4: A New Player in Cardiometabolic Disease?

Authors:  Gage M Stuttgen; Daisy Sahoo
Journal:  Endocrinology       Date:  2021-08-01       Impact factor: 5.051

Review 6.  P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases.

Authors:  Derek Strassheim; Alexander Verin; Robert Batori; Hala Nijmeh; Nana Burns; Anita Kovacs-Kasa; Nagavedi S Umapathy; Janavi Kotamarthi; Yash S Gokhale; Vijaya Karoor; Kurt R Stenmark; Evgenia Gerasimovskaya
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

7.  Atorvastatin combined with low-dose dexamethasone for vascular endothelial cell dysfunction induced by chronic subdural hematoma.

Authors:  Yue-Shan Fan; Bo Wang; Dong Wang; Xin Xu; Chuang Gao; Ying Li; Shu Zhang; Gui-Li Yang; Xiao Liu; Rong-Cai Jiang; Jian-Ning Zhang
Journal:  Neural Regen Res       Date:  2021-03       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.